On July 19, 2023, Passage Bio, Inc. announced an organizational redesign intended to better align the Company?s resources with its previously announced focused research and development strategy and further extend its cash runway. In connection with this organizational redesign, as further described below, Alex Fotopoulos, the Company?s Chief Technical Officer, will separate from the Company, effective on or about July 28, 2023. The Company also expects to enter into a consulting agreement with Mr. Fotopoulos to continue to provide certain services to the Company through July 28, 2024.

On July 15, 2023, Kathleen Borthwick, the current Vice President, Finance of the Company was appointed to serve as Senior Vice President, effective on or about July 28, 2023 (the ?Commencement Date?). In this role, Ms. Borthwick will assume the responsibilities of the Company?s Principal Financial Officer and Principal Accounting Officer. Ms. Borthwick, age 47, will serve as Senior Vice President and Interim Chief Financial Officer effective July 28, 2023.

From November 2021 to July 2023, Ms. Borthwick served as Vice President of Finance. From June 1997 to October 2021, Ms. Borthwick served in various leadership roles of increasing responsibility at Johnson & Johnson. During her tenure at Johnson & Johnson, she worked in Finance in support of Research & Development, Manufacturing, Business Development, Treasury and commercial operations for global Pharmaceutical and Medical Technology business segments.

Ms. Borthwick earned her B.S. in Economics with concentrations in Accounting and Health Care Management at the Wharton School of University of Pennsylvania, and her M.B.A. from the Tuck School of Business at Dartmouth College.